Cancer Therapies
Cancer Therapies
Treatment Resistant Cancers
Cancer
Targeted Cancer Therapies
Cancer Vaccines
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 7, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Li Zhang1, Han-Dong Wang, Xiang-Jun Ji
1Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China.
FTY720, an FDA-approved multiple sclerosis drug, also demonstrates preclinical antitumor effects. Unphosphorylated FTY720 targets cancer via S1PR-independent mechanisms, distinct from its immunosuppressive action.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: